The S&P 500 rallied in the wake of last week's election results, climbing 3.8% since Nov. 5 at Wednesday's prices. But not ...

SPDR® S&P Biotech ETF is a well-diversified, low-cost ETF that can be an excellent tool to capitalize on the potential of the biotech stock sector. XBI's performance should be compared with the ...

The Invesco Biotechnology & Genome ETF (PBE) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

A smart beta exchange traded fund, the SPDR S&P Biotech ETF (XBI) debuted on 01/31/2006, and offers broad exposure to the Health Care ETFs category of the market. Products that are based on market ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

iShares Biotechnology ETF Trading Down 0.2 % Shares of IBB opened at $142.42 on Wednesday. iShares Biotechnology ETF has a fifty-two week low of $111.83 and a fifty-two week high of $150.57. The ...

In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Legend Biotech (LEGN – Research Report).

the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund launched on 12/20/2011. Passively managed ETFs are becoming increasingly popular with institutional as well as retail ...

Biotech stocks can be incredibly attractive for risk-taking investors because of their ability to go parabolic in an instant.